About Haemopharm Healthcare
Founded in the 1970s on the foundations of the family company Gobbi Frattini, a pioneer in the medical devices sector, Haemopharm Healthcare has achieved a leading role in the international market, qualifying itself as a leader in the infusion sector. The company is characterized by a very high level of specialization, a constant commitment to research and development of innovative solutions, and exclusive and proprietary technology of its machines.
The company portfolio includes a wide range of flexible PVC and PVC-FREE bags for sterile solutions, delivery systems, and infusion components, for several pharmaceutical and medical applications. The company also offers a filling service that is carried out in Contract Manufacturing.
Haemopharm solutions are highly innovative, designed and manufactured entirely in-house, in the Lombard plant of Tovo S. Agatha (SO), in compliance with the most rigorous and high-quality standards.
Modular production management ensures maximum efficiency, through versatile and cutting-edge processes, high product reliability and constant performance levels over time.
“Innofamily since 70’s”
Over the years Haemopharm has always remained consistent with its identity values, rooted in the entrepreneurial history of the Gobbi Frattini family, which from the very beginning has played a leading role in the automated production of flexible bags for the biomedical sector.
Family tradition and innovation are effectively combined in Haemopharm’s claim – “Innofamily since 70’s” – which fully expresses the company’s identity and the foundations of its positioning.
The proprietary technology of the machines
In the 70s, Renzo Gobbi Frattini, founder of the company, personally designed the first generation of Haemopharm machines for the manufacture of biomedical sterile bags, making use of his expertise and passion in the engineering field. This added value has allowed the company to play a pioneering role and set new standards for the sector.
The machines for the production of sterile bags designed in-house still represent a flagship of the company, and one of its most important competitive advantages.
The vocation to innovate is a “family” prerogative
The current owner Paolo Gobbi Frattini, head of the company for the second generation, has followed in his father’s footsteps with equal determination and success, focusing on the design of cutting-edge systems and components for drug delivery, developed and produced entirely in-house. Many of these are patented and proprietary, with unique features on the market.
Direct commitment of the owner to the company management
The owner Paolo Gobbi Frattini, whose family owns 100% of the share capital, is present and operational in the Group, guaranteeing a long-term perspective. This is another key aspect of corporate identity, which facilitates communication and accelerates the decision-making process, to better meet the needs of customers.
A dynamic entrepreneurial spirit, constantly oriented towards the pursuit of excellence in over thirty years of history, places at the center of the Company’s strategy, three fundamental strategic assets that represent the Pillars of the Haemopharm Vision, and the foundations of its competitiveness:
● OF PROCESSES, thanks to the proprietary technology of the machines, to the modular and versatile management of production;
● OF PRODUCTS, because the company develops solutions with advanced functional features, with high added value;
● OF COMPETENCES, because Haemopharm professionals have high-level specialist skills, always working with a cutting-edge design approach.
Because Haemopharm solutions meet the needs of various therapeutic areas, such as pharmaceutical compounding, drug reconstitution, dialysis, nutrition, cryopreservation of cells and tissues, ozone therapy and ophthalmology.
Because thanks to a consolidated network of partnerships and collaborations, Haemopharm is able to activate strategic collaborations along the supply chain, and to manage every phase of the project with the highest quality and efficiency, and in a short time.
The company’s mission is to consolidate its own leadership technologically, developing numerous patents and following sustainable growth, as a partner of choice for big international entities.
Its international expansion strategy is included in a wider growth logic, oriented towards offering a modern and dynamic organization, capable of competing globally and being the first to reach specialist market areas with high-quality products.
A worldwide commercial network
The global competitive ability of Haemopharm is an aspect of the crucial importance of company policy. The customers, in fact, are increasingly sensitive regarding the launch of new business relationships with operators in the sector, who can not only offer an excellent product but are also able to guarantee an extensive presence worldwide, thanks to the support of strategic partnerships.
For these reasons Haemopharm has developed over the years many strategic commercial agreements, thanks to which it is now present and active in many countries across Europe, North and South America, Australia and the Far East, thanks to which it is able to preside over the geographical areas of most interest to their business.
Direct presence in Serbia, through Quatalia Science d.o.o.
With headquarters in Belgrade, Quatalia Science d.o.o is a company controlled by Haemopharm which has been established to consolidate local business and to facilitate the emerging markets penetration. Quatalia also deals with the recording of numerous Marketing Authorizations, especially for oncological treatment, antibiotics and medical devices.
Competence and constant updates on Regulatory Affairs
Both the companies – Haemopharm and Quatalia – have their own Regulatory Affairs departments, in charge of supervising the Marketing Authorization procedures, through dossiers preparation for drugs, and technical files for the CE-marked medical devices.
The acquisition of FDA Certifications, necessary for the commercialization of medical devices in the USA, represents, moreover, an important step in Haemopharm’s development strategy.
A network of partnerships and business relationships, nationally and internationally, allows us to extend our range of action and activate synergies along the supply chain.
Thanks to the collaboration with accredited companies in the sector, Haemopharm is able to manage every phase of the project on behalf of the customer and to propose high-quality solutions, with maximum efficiency and in reduced time.
From the collaboration with SIAD, ADVATIS is born
In May 2005, Haemophorm signed o cooperation agreement with the company SIAD Healthcare for the development, production and marketing of a new line of bags for cryopreservation of stem cells and tissues: SAFE2.
The agreement with SIAD Healthcare expands Haemopharm’s presence in a new market segment and allows the company, through the Life Science Division of SIAD, to be supported by a trusted partner to continue the search for innovative solutions for cell therapies. The goal for both companies is to produce products that fully meet the stringent demands of the customers.
In 2015, the continuous collaboration with SIAD Healthcare becomes a contractual joint venture: ADVATIS, “Advanced Therapies Innovative Solutions” is born, which provides the market with innovative solutions in the field of cryopreservation and cell therapy, offering a wide range of products that cover the different stages of collection, manipulation and preservation of stem cells and tissues.
Thanks to a high level of flexibility and with the support of the R & D team, ADVATIS can offer tailored solutions to meet any customer demand.
From industrial research to treatment
Haemopharm is a unique entrepreneurial structure, due to its clinical division, the St. Agatha Medical Center, which faithfully represents the company’s DNA and its natural tendency to a tight collaboration with the medical-scientific world.
The current and future success of Haemopharm Healthcare is grounded on a solid foundation of ethical values, at the core of its day-to-day activities which became the official operating guidelines adopted by the Company. Responsibility, an ethical approach to our work and the ability to form genuine partnerships with our customers, respect for people, the transparency of business activities, impartiality in the management of human resources, the honesty and clarity of contracts, a commitment to obligations undertaken, observance of the law, and respect for institutions in all countries across the world: these are the underpinning values, which are combined with a customer-oriented culture, with which Haemopharm aims to establish solid and lasting partnerships.
Haemopharm Healthcare is also responsible and committed to the environment, sustainable development, and to the search for technical solutions that enable us to make better use of resources and reduce environmental impact.